Evaluation of protective effects of GnRH agonist or antagonist on ovarian reserve with anti-Müllerian hormone and histological analysis in a rat model using cisplatin

• Published in: Archives of medical science Vol. 19; no. 2; pp. 448 - 451
• Main Authors: Tas, Mustafa, Oner, Gokalp, Ulug, Pasa, Yavuz, Adem, Ozcelik, Bulent
• Format: Journal Article
• Language: English
• Published: Poland Termedia Publishing House 2023
• Subjects: anti-müllerian hormone; cisplatin; Experimental Research; ovarian reserve; cisplatin; anti-Müllerian hormone; ovarian reserve
• ISSN: 1734-1922; 1896-9151
• DOI: 10.5114/aoms.2019.87540

The aim of this prospective trial was to evaluate the ovarian reserve with anti-Müllerian hormone (AMH), which is the best predictor of ovarian reserve, and perform histological analysis after exposure to cisplatin with a GnRH agonist or antagonist. Twenty-four Wistar albino rats were randomly divided into three groups, each consisting of eight rats. In the GnRH agonist group (group 1), rats received a single dose of 50 mg/m cisplatin with 1 mg/kg triptorelin. In the GnRH antagonist group (group 2), rats received a single dose of 50 mg/m cisplatin with 1 mg/kg cetrorelix. In the control group (group 3), rats received 50 mg/m cisplatin. Ovarian reserve was assessed by AMH and histology. Primary follicle counts were higher in group 2 (4.50 ±1.47 vs. 3.50 ±1.70 vs. 3.00 ±3.54) and secondary follicle counts were higher in group 1 (2.96 ±1.11 vs. 1.74 ±1.03 vs. 1.37 ±3.11). Numbers of tertiary follicles were higher both in groups 1 and 2 than the control group (1.36 ±0.83 vs. 0.84 ±0.99 vs. 0.50 ±0.75). The total follicle count of the study groups were significantly higher compared with the control group (14.32 ±5.96 vs. 12.48 ±4.12 vs. 10.63 ±6.80). AMH was significantly higher in groups 1 and 2 compared with the control group (18.56 ±25.33 vs. 16.48 ±24.66 vs. 9.37 ±26.54). This is the first prospective randomized controlled study showing the protective effects of GnRH agonist and antagonist on ovarian reserve after cisplatin exposure in an animal model.